Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126764741 | 12676474 | 1 | I | 20120510 | 20160818 | 20160823 | 20160823 | EXP | JP-GLAXOSMITHKLINE-JP2016JPN119671 | GLAXOSMITHKLINE | 58.86 | YR | M | Y | 0.00000 | 20160823 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126764741 | 12676474 | 1 | SS | Dolutegravir | DOLUTEGRAVIR | 1 | Oral | 50 MG, UNK | 0 | 50 | MG | FILM-COATED TABLET | |||||||
| 126764741 | 12676474 | 2 | PS | EPIVIR | LAMIVUDINE | 1 | Oral | 150 MG, QD | 20564 | 150 | MG | TABLET | QD | ||||||
| 126764741 | 12676474 | 3 | SS | ZIAGEN | ABACAVIR SULFATE | 1 | Oral | 300 MG, BID | 0 | 300 | MG | FILM-COATED TABLET | BID | ||||||
| 126764741 | 12676474 | 4 | SS | ISENTRESS | RALTEGRAVIR POTASSIUM | 1 | 400 MG, BID | 6400 | MG | N | 0 | 400 | MG | TABLET | BID | ||||
| 126764741 | 12676474 | 5 | C | EPZICOM | ABACAVIR SULFATELAMIVUDINE | 1 | Oral | 1 DF, UNK | 0 | 1 | DF | FILM-COATED TABLET | |||||||
| 126764741 | 12676474 | 6 | C | ZITHROMAC | AZITHROMYCIN DIHYDRATE | 1 | 1200 MG, WE | 0 | 1200 | MG | /wk | ||||||||
| 126764741 | 12676474 | 7 | C | TAKEPRON | LANSOPRAZOLE | 1 | 15 MG, QD | 0 | 15 | MG | QD | ||||||||
| 126764741 | 12676474 | 8 | C | PENTAMIDINE ISETIONATE | PENTAMIDINE ISETHIONATE | 1 | 300 MG, ONCE A MONTH | 0 | 300 | MG | |||||||||
| 126764741 | 12676474 | 9 | C | AMLODIN | AMLODIPINE BESYLATE | 1 | 5 MG, QD | 0 | 5 | MG | QD | ||||||||
| 126764741 | 12676474 | 10 | C | NU-LOTAN | LOSARTAN POTASSIUM | 1 | 50 MG, QD | 0 | 50 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126764741 | 12676474 | 1 | HIV infection |
| 126764741 | 12676474 | 2 | HIV infection |
| 126764741 | 12676474 | 3 | HIV infection |
| 126764741 | 12676474 | 4 | HIV infection |
| 126764741 | 12676474 | 5 | HIV infection |
| 126764741 | 12676474 | 6 | Opportunistic infection prophylaxis |
| 126764741 | 12676474 | 7 | Gastrooesophageal reflux disease |
| 126764741 | 12676474 | 8 | Antifungal prophylaxis |
| 126764741 | 12676474 | 9 | Hypertension |
| 126764741 | 12676474 | 10 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126764741 | 12676474 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126764741 | 12676474 | Osteoporosis | |
| 126764741 | 12676474 | Renal impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126764741 | 12676474 | 1 | 20150826 | 0 | ||
| 126764741 | 12676474 | 2 | 20120519 | 0 | ||
| 126764741 | 12676474 | 3 | 20120519 | 0 | ||
| 126764741 | 12676474 | 4 | 20120502 | 20150825 | 0 | |
| 126764741 | 12676474 | 5 | 20120502 | 20120518 | 0 | |
| 126764741 | 12676474 | 6 | 20130214 | 20150825 | 0 | |
| 126764741 | 12676474 | 10 | 20150513 | 0 |